Liraglutide's Efficacy for Blood Glucose Control in Type 2 Diabetes Evaluated in Randomized Phase 3 Trial

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by elevated blood glucose levels due to insulin resistance and/or insufficient insulin production. Uncontrolled hyperglycemia leads to severe microvascular and macrovascular complications. Current treatments often involve lifestyle modifications, metformin, and other glucose-lowering agents, but many patients struggle to achieve optimal glycemic control, highlighting the need for more effective and well-tolerated therapies. Glucagon-like peptide-1 (GLP-1) receptor agonists, like liraglutide, offer a promising mechanism by enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. This trial aims to rigorously evaluate liraglutide's role in improving glycemic outcomes.

This multi-national, randomized, double-blind, placebo-controlled, parallel-group Phase 3 trial enrolled 400 subjects with Type 2 Diabetes. Participants were randomly assigned with equal chance to receive either Liraglutide or placebo, administered by subcutaneous injection once daily in the evening for a duration of 14 weeks. Treatment allocation was concealed from subjects, investigators, and the sponsor. The primary endpoint of the study was to demonstrate the effect of treatment with liraglutide on blood glucose control.